Press coverage about Prothena (NASDAQ:PRTA) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prothena earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.6019988836764 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of analysts recently weighed in on the stock. ValuEngine raised shares of Prothena from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Oppenheimer set a $70.00 price objective on shares of Prothena and gave the company a “buy” rating in a research report on Monday, December 4th. Deutsche Bank set a $73.00 price objective on shares of Prothena and gave the company a “buy” rating in a research report on Monday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $65.00 price objective on shares of Prothena in a research report on Wednesday, December 20th. Finally, Wedbush cut shares of Prothena from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $75.00 to $55.00 in a research report on Monday, November 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $75.58.
Shares of Prothena (PRTA) opened at $36.77 on Tuesday. The stock has a market cap of $1,410.00, a PE ratio of -8.67 and a beta of 2.42. Prothena has a 12 month low of $34.85 and a 12 month high of $70.00.
In related news, insider Tara Nickerson sold 4,724 shares of the stock in a transaction dated Wednesday, September 27th. The shares were sold at an average price of $69.05, for a total transaction of $326,192.20. Following the sale, the insider now owns 6,724 shares in the company, valued at $464,292.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christopher S. Henney sold 900 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $70.00, for a total transaction of $63,000.00. Following the completion of the transaction, the director now owns 900 shares of the company’s stock, valued at approximately $63,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,924 shares of company stock worth $809,787. 3.10% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Prothena (PRTA) Given News Sentiment Rating of 0.13” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/26/prothena-prta-given-news-sentiment-rating-of-0-13.html.
Prothena Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.